Wednesday, June 16, 2021 Daily Archives

GSK pays iTeos $625m for anti-TIGIT mAb

by

GSK has the leading portfolio of antibodies targeting immune-oncology therapies as it agrees to co-develop and commercialize EOS-448 with iTeos. British firm GlaxoSmithKline (GSK) has agreed to an upfront payment of $625 million to iTeos Therapeutics. However, the deal could be worth $1.45 billion with potential milestones and royalty payments dependent on the success of EOS-448. EOS-448 is an anti-T cell immunoreceptor with Ig and ITIM domains (TIGIT) monoclonal antibody (mAb), which is currently in Phase I development as a…

June 16, 2021

Beyond the CDMO: Samsung Biologics reveals Big Pharma ambition

by

Having grown into one of the world’s largest bio-CDMOs over the past decade, Samsung Biologics says its next step is to become a top tier pharmaceutical company. Incheon, Korea-based contract development and manufacturing organization (CDMO) Samsung Biologics boasts three plants hosting a total of 364,000 L of mostly stainless-steel bioreactor capacity. Last year, the firm began construction on a fourth facility, housing an additional 256,000 liters of mammalian production capacity as well as fill/finish capabilities. “it’s going to be delivered…

June 16, 2021

Avalon to buy China’s Senlang for cell therapy pipeline and manufacturing plant

by

Avalon GloboCare will buy Chinese cell therapy developer Hebei Senlang Biotechnology in a deal prompted by the latter’s pipeline and biomanufacturing capacity. The deal – which will see Avalon issue 81 million shares – will also include Senlang’s chimeric antigen receptor T-cells, allogeneic CAR Gamma Delta T-cells, and armored tumor infiltrating lymphocyte (armTILs) platforms. Avalon will also gain SenlangBio Clinical Laboratory, a subsidiary that provides third-party services. The firm specializes in biochemical, genomic and proteomic testing, cell therapy related analysis…

June 16, 2021